Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Retractable Rejected by Top Court on Becton Patent Appeal

Don't Miss Out —
Follow us on:

Jan. 7 (Bloomberg) -- The U.S. Supreme Court rejected an appeal by Retractable Technologies Inc. in its patent suit against Becton, Dickinson & Co. over technology used to protect health-care workers from accidental needle sticks.

Retractable was seeking to overturn a federal appeals court decision that struck down part of a $5 million jury award.

The U.S. Court of Appeals for the Federal Circuit ruled in July that Becton’s 3-milliliter Integra syringe doesn’t violate Retractable’s patents. The appeals court upheld the jury’s separate finding against Becton over its 1-milliliter Integra product. The patents cover Retractable’s VanishPoint-brand syringes, which contain spring-loaded needles.

Retractable, based in Little Elm, Texas, is also pressing an antitrust case against Becton, based in Franklin Lakes, New Jersey.

The case is Retractable Technologies v. Becton Dickinson, 11-1154.

To contact the reporter on this story: Greg Stohr in Washington at gstohr@bloomberg.net

To contact the editor responsible for this story: Steven Komarow at skomarow1@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.